Everolimus

Generic Name: Everolimus

Brand Names: Afinitor, Votubia, Zortress

Drug Type: Small Molecule

Chemical Formula: C_₅₃H_₈₃NO_₁₄

CAS Number: 159351-69-6

Unique Ingredient Identifier: 9HW64Q8G6G

Background: Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication: Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions: Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors

Associated Therapies: -

Clinical Trials

Liver Transplantation With Tregs at UCSF

Phase 1

Terminated

Conditions: Liver Transplant

Interventions: Biological: arTreg
Procedure: leukapheresis
Drug: cyclophosphamide
Drug: mesna
Drug: everolimus

First Posted Date: 2018-08-31

Last Posted Date: 2024-04-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 42

Registration Number: NCT03654040

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas

Phase 2

Withdrawn

Conditions: Diffuse Intrinsic Pontine Glioma
Glioma

Interventions: Drug: Panobinostat
Drug: Everolimus

First Posted Date: 2018-08-15

Last Posted Date: 2019-08-19

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT03632317

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue

Phase 1

Conditions: Neuroendocrine Tumors

Interventions: Drug: Everolimus

First Posted Date: 2018-08-14

Last Posted Date: 2018-08-14

Lead Sponsor: King Faisal Specialist Hospital & Research Center

Target Recruit Count: 30

Registration Number: NCT03629847

Locations: 🇸🇦
Oncology Centre, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia

Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency

Phase 3

Conditions: Prostate Cancer

Interventions: Drug: Placebo
Drug: Everolimus

First Posted Date: 2018-07-09

Last Posted Date: 2018-07-09

Lead Sponsor: Tianjin Medical University Second Hospital

Target Recruit Count: 120

Registration Number: NCT03580239

Locations: 🇨🇳
The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, Tianjin, China
🇨🇳
Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China
🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China

and more 1 locations